|

Autonomic Modulation in Takotsubo Syndrome

RECRUITINGN/ASponsored by NYU Langone Health
Actively Recruiting
PhaseN/A
SponsorNYU Langone Health
Started2021-10-01
Est. completion2027-06
Eligibility
Age21 Years+
Healthy vol.Accepted
Locations1 site

Summary

This is a minimal risk case-controlled single arm intervention study, including 10 patients with a prior history of takotsubo and 10-age and sex matched healthy controls. Subjects will undergo in laboratory testing to measure autonomic function. They will then undergo a 15-week program of device-guided breathing with remote measures of autonomic function obtained at home. Analysis will determine the reproducibility of home autonomic measures and the provide preliminary data to determine the efficacy of device-guided breathing on autonomic measures and quality of life in patients with takotsubo.

Eligibility

Age: 21 Years+Healthy volunteers accepted
Inclusion Criteria:

* Confirmed history of takotsubo syndrome
* Healthy person with no significant past history of cardiovascular or neurological disease such as heart failure or heart attack; people with cardiovascular risk factors such as hypertension will be permitted to participate

Exclusion Criteria:

* Pacemaker or defibrillator implanted
* Evidence of autonomic neuropathy, alcohol or drug abuse or exposure to neurotoxins (chemotherapy).
* Diabetes

Conditions2

Heart DiseaseTakotsubo Syndrome

Locations1 site

New York University School of Medicine
New York, New York, 10016
Harmony Reynolds646-501-0302harmony.reynolds@nyumc.org

Browse More Trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.